Extended-spectrum beta-lactamases. An overview.

Research output: Contribution to journalArticle

Abstract

The emergence of extended-spectrum beta-lactamase (ESBL)- producing Klebsiella pneumoniae and other ESBL-producing Enterobacteriaceae is an increasing problem and presents a dilemma for clinicians. The problem is not only detection of this resistance in the microbiology laboratory, but also a therapeutic dilemma due to multiple drug resistance to extended-spectrum beta-lactams and other agents, including fluoroquinolones, trimethoprim-sulfamethoxazole, and gentamicin. Currently, imipenem appears to be the drug of choice for serious infections due to these isolates, based on accumulating clinical experience. Because options for therapy are limited, control and prevention measures are particularly important. These should include not only traditional infection control measures such as contact precautions, but also antibiotic utilization measures, such as widespread empiric use of ceftazidime.

Original languageEnglish (US)
Pages (from-to)32-38
Number of pages7
JournalPostgraduate Medicine
Volume109
Issue number2 Suppl
StatePublished - Feb 2001

Fingerprint

beta-Lactamases
Ceftazidime
Imipenem
Fluoroquinolones
Sulfamethoxazole Drug Combination Trimethoprim
Klebsiella pneumoniae
beta-Lactams
Multiple Drug Resistance
Enterobacteriaceae
Infection Control
Microbiology
Gentamicins
Anti-Bacterial Agents
Therapeutics
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Extended-spectrum beta-lactamases. An overview. / Patterson, Jan E.

In: Postgraduate Medicine, Vol. 109, No. 2 Suppl, 02.2001, p. 32-38.

Research output: Contribution to journalArticle

@article{d453c522b9e144219c432e4616ec3609,
title = "Extended-spectrum beta-lactamases. An overview.",
abstract = "The emergence of extended-spectrum beta-lactamase (ESBL)- producing Klebsiella pneumoniae and other ESBL-producing Enterobacteriaceae is an increasing problem and presents a dilemma for clinicians. The problem is not only detection of this resistance in the microbiology laboratory, but also a therapeutic dilemma due to multiple drug resistance to extended-spectrum beta-lactams and other agents, including fluoroquinolones, trimethoprim-sulfamethoxazole, and gentamicin. Currently, imipenem appears to be the drug of choice for serious infections due to these isolates, based on accumulating clinical experience. Because options for therapy are limited, control and prevention measures are particularly important. These should include not only traditional infection control measures such as contact precautions, but also antibiotic utilization measures, such as widespread empiric use of ceftazidime.",
author = "Patterson, {Jan E}",
year = "2001",
month = "2",
language = "English (US)",
volume = "109",
pages = "32--38",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "2 Suppl",

}

TY - JOUR

T1 - Extended-spectrum beta-lactamases. An overview.

AU - Patterson, Jan E

PY - 2001/2

Y1 - 2001/2

N2 - The emergence of extended-spectrum beta-lactamase (ESBL)- producing Klebsiella pneumoniae and other ESBL-producing Enterobacteriaceae is an increasing problem and presents a dilemma for clinicians. The problem is not only detection of this resistance in the microbiology laboratory, but also a therapeutic dilemma due to multiple drug resistance to extended-spectrum beta-lactams and other agents, including fluoroquinolones, trimethoprim-sulfamethoxazole, and gentamicin. Currently, imipenem appears to be the drug of choice for serious infections due to these isolates, based on accumulating clinical experience. Because options for therapy are limited, control and prevention measures are particularly important. These should include not only traditional infection control measures such as contact precautions, but also antibiotic utilization measures, such as widespread empiric use of ceftazidime.

AB - The emergence of extended-spectrum beta-lactamase (ESBL)- producing Klebsiella pneumoniae and other ESBL-producing Enterobacteriaceae is an increasing problem and presents a dilemma for clinicians. The problem is not only detection of this resistance in the microbiology laboratory, but also a therapeutic dilemma due to multiple drug resistance to extended-spectrum beta-lactams and other agents, including fluoroquinolones, trimethoprim-sulfamethoxazole, and gentamicin. Currently, imipenem appears to be the drug of choice for serious infections due to these isolates, based on accumulating clinical experience. Because options for therapy are limited, control and prevention measures are particularly important. These should include not only traditional infection control measures such as contact precautions, but also antibiotic utilization measures, such as widespread empiric use of ceftazidime.

UR - http://www.scopus.com/inward/record.url?scp=69249222797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249222797&partnerID=8YFLogxK

M3 - Article

C2 - 19667555

AN - SCOPUS:69249222797

VL - 109

SP - 32

EP - 38

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 2 Suppl

ER -